Abstract Purpose of Review Chemotherapy remains the first-line therapy for aggressive
lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15 …

Historically, high levels of treatment-related mortality restricted the use of standard
myeloablative allogeneic stem-cell transplantation to a minority of young and fit patients with …

Background Allogeneic hematopoetic stem-cell transplantation (alloHSCT) has curative
potential for poor risk lymphoma patients due to the graft-versus-lymphoma effect. High non …

The primary objective of this study was to evaluate the outcome of patients treated with high-
dose chemo-/radiotherapy or high-dose chemotherapy and autologous stem-cell transplant …

Allogeneic transplantation of hematopoietic stem cells (allo-SCT) is being increasingly used
to treat patients with lymphoma. We describe current results of allo-SCT in patients with …

High-dose chemotherapy and autologous stem cell transplant (ASCT) is the standard
approach for chemosensitive, relapsed aggressive non-Hodgkin's lymphoma (NHL). Various …

Background The efficacy of autologous stem-cell transplantation during the first remission in
patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate …

This study was conducted to compare the results of myeloablative therapy followed either by
autologous stem cell transplantation (SCT) or allogeneic SCT for poor-risk low-grade non …

Purpose Our objective was to evaluate the impact of high-dose therapy and autologous
bone marrow transplantation as salvage treatment for recurrent non-Hodgkin's lymphoma in …

We investigated the impact of the most commonly used preparative regimens on the
outcome of 395 patients with diffuse large cell lymphoma (DLCL), consecutively reported to …